5. The material according to claim 1, wherein the purifying comprises the following protocol:

plasma cleared by centrifugation;

cleared plasma spun to give a nominal 0-30 kD fraction;

nominal 0-30 kD fraction spun to give a nominal 10-30 kD sub-fraction;

nominal 10-30 kD sub-fraction concentrated and gel-filtered to give a nominal 10-20 kD sub-fraction;

nominal 10-20 kD sub-fraction repeatedly concentrated and buffer-diluted, applied to an ion exchange column eluted with a gradient of 0-.3 M NaCl; and

eluate divided into 0-0.1 M, 0.1-0.2 M and 0.2-0.3 M NaCl ion exchange fractions.

6. The material according to claim 1, wherein the mammal is a sheep.

8. A pharmaceutical composition comprising a material having the ability to reduce organ mass, the material being obtainable by:

collecting ovarian venous blood from a female mammal;

preparing ovarian venous plasma from the blood; and

at least partially purifying said material from the plasma

and a pharmaceutically acceptable excipient or carrier.

Please cancel claims 7 and 9 and add the following new claims:

10. The pharmaceutical composition, according to claim 8, wherein the purifying comprises obtaining the 1-30 kD fraction.

11. The pharmaceutical composition, according to claim 8, wherein the purifying comprises obtaining the 10-20 kD fraction.

12. The pharmaceutical composition, according to claim 8, wherein the purifying additionally comprises ion exchange chromatography, and collecting the fraction eluted in 0.1-0.2 M NaCl.

13. The pharmaceutical composition, according to claim 8, wherein the purifying comprises the following protocol:

plasma cleared by centrifugation;

cleared plasma spun to give a nominal 0-30 kD fraction;

nominal 0-30 kD fraction spun to give a nominal 10-30 kD sub-fraction;

nominal 10-30 kD sub-fraction concentrated and gel-filtered to give a nominal 10-20 kD sub-fraction;

nominal 10-20 kD sub-fraction repeatedly concentrated and buffer-diluted, applied to an ion exchange column eluted with a gradient of 0-.3 M NaCl; and

eluate divided into 0-0.1 M, 0.1-0.2 M and 0.2-0.3 M NaCl ion exchange fractions.

14. The pharmaceutical composition, according to claim 8, wherein the mammal is a sheep.

15. A method for treating organ or tissue hypertrophy wherein said method comprises administering, to a patient in need of such treatment, an effective amount of a material having the ability to reduce organ mass, the material being obtainable by:

collecting ovarian venous blood from a female mammal;

preparing ovarian venous plasma from the blood; and

at least partially purifying said material from the plasma.

16. The method, according to claim 15, wherein the purifying comprises obtaining the 1-30 kD fraction.

17. The method, according to claim 15, wherein the purifying comprises obtaining the 10-20 kD fraction.

18. The method, according to claim 15, wherein the purifying additionally comprises ion exchange chromatography, and collecting the fraction eluted in 0.1-0.2 M NaCl.

19. The method, according to claim 15, wherein the purifying comprises the following protocol:

plasma cleared by centrifugation;

cleared plasma spun to give a nominal 0-30 kD fraction;

nominal 0-30 kD fraction spun to give a nominal 10-30 kD sub-fraction;

nominal 10-30 kD sub-fraction concentrated and gel-filtered to give a nominal 10-20 kD sub-fraction;

nominal 10-20 kD sub-fraction repeatedly concentrated and buffer-diluted, applied to an ion exchange column eluted with a gradient of 0-.3 M NaCl; and

eluate divided into 0-0.1 M, 0.1-0.2 M and 0.2-0.3 M NaCl ion exchange fractions.

20. The method, according to claim 15, wherein the mammal is a sheep.